2021.6.13

2020

Non-Refereed papers

_____,_____, .
β .
2020; 62: 112-117.

1 _____
, 2020 1 21 ,

2 _____
, 2020 1 31 ,

3 _____
, 2020 2 8 ,

4 _____
, 2020 2 10 ,

5 _____
RMA
2 , 2020 2 11 ,

6 _____
, 2020 2 26 ,

7 _____
patient engagement
, 2020 10 6 ,

8 _____
135 , 2020 10 21 ,

9 _____ _____
30 , 2020 10 24 11 1 web

2021.6.13

10 _____ _____

30 , 2020 10 24 11 1 web

11 _____

50 , 2020 10 31 11 8 web

12 _____

Web 2020, 2020 11 11 ,

13 _____

implementation science

, 2020 11 15 ,

Refereed papers

1. Walsh R, Lahrouchi N, Tadros R, Kyndt F, Glinge C, Postema PG, Amin AS, Nannenberg EA, Ware JS, Whiffin N, Mazzarotto F, Škorić-Milosavljević D, Krijger C, Arbelo E, Babuty D, Barajas-Martinez H, Beckmann BM, Bézieau S, Bos JM, Breckpot J, Campuzano O, Castelletti S, Celen C, Clauss S, Corveleyn A, Crotti L, Dagradi F, de Asmundis C, Denjoy I, Dittmann S, Ellinor PT, Ortuño CG, Giustetto C, Gourraud JB, Hazeki D, Horie M, Ishikawa T, Itoh H, Kaneko Y, Kanters JK, Kimoto H, Kotta MC, Krapels IPC, Kurabayashi M, Lazarte J, Leenhardt A, Loeys BL, Lundin C, Makiyama T, Mansourati J, Martins RP, Mazzanti A, Mörner S, Napolitano C, Ohkubo K, Papadakis M, Rudic B, Molina MS, Sacher F, Sahin H, Sarquella-Brugada G, Sebastiano R, Sharma S, Sheppard MN, Shimamoto K, Shoemaker MB, Stallmeyer B, Steinfurt J, Tanaka Y, Tester DJ, Usuda K, van der Zwaag PA, Van Dooren S, Van Laer L, Winbo A, Winkel BG, Yamagata K, Zumhagen S, Volders PGA, Lubitz SA, Antzelevitch C, Platonov PG, Odening KE, Roden DM, Roberts JD, Skinner JR, Tfelt-Hansen J, van den Berg MP, Olesen MS, Lambiase PD, Borggrefe M, Hayashi K, Rydberg A, Nakajima T, Yoshinaga M, Saenen JB, Kääb S, Brugada P, Robyns T, Giachino DF, Ackerman MJ, Brugada R, Brugada J, Gimeno JR, Hasdemir C, Guicheney P, Priori SG, Schulze-Bahr E, Makita N, Schwartz PJ, Shimizu W, Aiba T, Schott JJ, Redon R, Ohno S, Probst V; Nantes Referral Center for inherited cardiac arrhythmia, Behr ER, Barc J, Bezzina CR.
   Enhancing rare variant interpretation in inherited arrhythmias through quantitative analysis of consortium disease cohorts and population controls.
   Genet Med. 2020; 23: 47-58.

2. Kojima A, Fukushima Y, Itoh H, Imoto K, Matsuura H.
A computational analysis of the effect of sevoflurane in a human ventricular cell model of long QT syndrome: Importance of repolarization reserve in the QT-prolonging effect of sevoflurane.
Eur J Pharmacol. 2020; 883: 173378.

3. Itoh H, Hisamatsu T, Tamura T, Segawa K, Takahashi T, Takada H, Kuru S, Wada C, Suzuki M, Suwazono S, Sasaki S, Okumura K, Horie M, Takahashi MP, Matsumura T.
Cardiac Conduction Disorders as Markers of Cardiac Events in Myotonic Dystrophy Type 1
JAHA: Journal of American Heart Association 2020; 9: e015709.

4. Lahrouchi N, Tadros R, Crotti L, Mizusawa Y, Postema PG, Beekman L, Walsh R, Hasegawa K, Barc J, Ernsting M, Turkowski KL, Mazzanti A, Beckmann BM, Shimamoto K, Diamant UB, Wijeyeratne YD, Kucho Y, Robyns T, Ishikawa T, Arbelo E, Christiansen M, Winbo A, Jabbari R, Lubitz SA, Steinfurt J, Rudic B, Loeys B, Shoemaker MB, Weeke PE, Pfeiffer R, Davies B, Andorin A, Hofman N, Dagradi F, Pedrazzini M, Tester DJ, Bos JM, Sarquella-Brugada G, Campuzano Ó, Platonov PG, Stallmeyer B, Zumhagen S, Nannenberg EA, Veldink JH, van den Berg LH, Al-Chalabi A, Shaw CE, Shaw PJ, Morrison KE, Andersen PM, Müller-Nurasyid M, Cusi D, Barlassina C, Galan P, Lathrop M, Munter M, Werge T, Ribasés M, Aung T, Khor CC, Ozaki M, Lichtner P, Meitinger T, van Tintelen JP, Hoedemaekers Y, Denjoy I, Leenhardt A, Napolitano C, Shimizu W, Schott JJ, Gourraud JB, Makiyama T, Ohno S, Itoh H, Krahn AD, Antzelevitch C, Roden DM, Saenen J, Borggrefe M, Odening KE, Ellinor PT, Tfelt-Hansen J, Skinner JR, van den Berg MP, Olesen MS, Brugada J, Brugada R, Makita N, Breckpot J, Yoshinaga M, Behr ER, Rydberg A, Aiba T, Kääb S, Priori SG, Guicheney P, Tan HL, Newton-Cheh C, Ackerman MJ, Schwartz PJ, Schulze-Bahr E, Probst V, Horie M, Wilde AA, Tanck MWT, Bezzina CR.
Transethnic Genome-Wide Association Study Provides Insights in the Genetic Architecture and Heritability of Long QT Syndrome.
Circulation. 2020; 142: 324-338.

5. cNally EM, Mann DL, Pinto Y, Bhakta D, Tomaselli G, Nazarian S, Groh WJ, Tamura T, Duboc D, Itoh H, Hellerstein L, Mammen PPA.
Clinical Care Recommendations for Cardiologists Treating Adults With Myotonic Dystrophy.
JAHA: Journal of American Heart Association 2020; 9(4): e014006.

Watadani Y, Ohge H, Hashimoto Y, Kondo N, Sakashita Y, Uemura K, Miyamoto K, Murakami Y, Hida E, Sueda T.
Validating the Japanese version of the Gastrointestinal Quality of Life Index (GIQLI) questionnaire
Annals of Gastrointestinal Surgery. 2020, First published: 18 July 2020 https://doi.org/10.1002/ags3.12376

7. Yamaguchi K, Iwamoto H, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Ohshimo S, Fujitaka K, Hamada H, Hattori N.
   Serum high-mobility group box 1 is associated with the onset and severity of acute exacerbation of idiopathic pulmonary fibrosis
   Respirology. 2020 ; 25(3) : 275-280.
8. Masuda T, Fujitaka K, Ishikawa N, Nakano K, Yamasaki M, Kitaguchi S, Masuda K, Yamaguchi K, Sakamoto S, Horimasu Y, Kawase S, Miyamoto S, Nakashima T, Iwamoto H, Shiota N, Senoo T, Awaya Y, Kondo T, Yoshida T, Hamada H, Murakami I, Hattori N.
   Treatment rationale and design of the PROLONG study: safety and efficacy of pembrolizumab as first-line therapy for elderly patients with non-small cell lung cancer
   J Thorac Dis. 2020 ; 12(3) : 1079-1084.
9. Nakanishi Y, Masuda T, Yamaguchi K, Sakamoto S, Horimasu Y, Mimae T, Nakashima T, Miyamoto S, Tsutani Y, Iwamoto H, Fujitaka K, Miyata Y, Hamada H, Okada M, Hattori N.
   Albumin-globulin ratio is a predictive biomarker of antitumor effect of anti-PD-1 antibody in patients with non-small cell lung cancer
   Int J Clin Oncol. 2020 ; 25(1) : 74-81.
10. Yamaguchi K, Iwamoto H, Mazur W, Miura S, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Ohshimo S, Fujitaka K, Hamada H, Hattori N.
    Reduced endogenous secretory RAGE in blood and bronchoalveolar lavage fluid is associated with poor prognosis in idiopathic pulmonary fibrosis
    Respir Res. 2020; 11;21(1):145.
11. Takao S, Masuda T, Yamada T, Yamaguchi K, Sakamoto S, Matsushima H, Horimasu Y, Nakashima T, Miyamoto S, Iwamoto H, Fujitaka K, Hamada H, Hattori N.
    Pulmonary arteriovenous malformation exhibiting recanalization >10 years after coil embolization: Two case reports
    Medicine (Baltimore). 2020; 99(2):e18694.
12 Wakabayashi Y, Masuda T, Fujitaka K, Nakashima T, Okumoto J, Shimoji K, Nishimura Y, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, Iwamoto H, Ohshimo S, Hamada H, Hattori N.
   Clinical significance of BIM deletion polymorphism in chemoradiotherapy for non-small cell lung cancer.
   Cancer Sci. 2020 Oct 26. doi: 10.1111/cas.14711.
13. Nakao S, Yamaguchi K, Iwamoto H, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S , Nakashima T, Ohshimo S, Fujitaka K , Hamada H , Hattori N.
    Serum high-mobility group box 1 as a predictive marker for cytotoxic chemotherapy-induced lung injury in patients with lung cancer and interstitial lung disease
    Respir Med. 2020 ; 172 : 106131.

14. Higaki N, Iwamoto H, Yamaguchi K, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Ohshimo S, Fujitaka K, Hamada H, Hattori N.
Correlations of forced oscillometric bronchodilator response with airway inflammation and disease duration in asthma
Clin Respir J. 2020 Aug 28. doi: 10.1111/crj.13268.

15. Nakanishi Y, Yamaguchi K, Yoshida Y, Sakamoto S, Horimasu Y, Masuda T, Nakashima T, Miyamoto S, Iwamoto H, Hirata S, Fujitaka K, Hamada H, Sugiyama E, Hattori N.
Coexisting TIF1 γ -positive Primary Pulmonary Lymphoepithelioma-like Carcinoma and Anti-TIF1 γ Antibody-positive Dermatomyositis
Intern Med. 2020 ; 59 : 2553-2558.

16. Namba M, Masuda T, Takao S, Terada H, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, Nakashima T, Iwamoto H, Ohshimo S, Fujitaka K, Hamada H, Awai K, Hattori N.
Extent of pulmonary fibrosis on high-resolution computed tomography is a prognostic factor in patients with pleuroparenchymal fibroelastosis
Respir Investig. 2020 ; 58 : 465-472.

17. _____

, 2020; 56: 299-304.

18. , _____, , , , , , ,
, .
1 .
, 2020; 56: 537-540.

19. _____

, 2020; 55:131-135

20. _____

, 2020; 9:191-194.

21. _____

Progress in Medicine, 2020; 40: 967-971.

22. _____, , , , , , , ,
, , .
Altemeier .
, 2020; 82: 1032-1035.

2021.6.13

1. _____. 4 . .
, , (2020)

1 _____

1 , 2020 2 12

2. _____

55 , 2020 2 20